

PRESENTED BY:



SPONSORED BY:



CONTINUING MEDICAL EDUCATION

Cancer Center Seminar Series - 5/5/2023 – 53044-52449

Date: May 5, 2023

Time: 12:00 PM-1:00 PM

Wolstein Bldg. Auditorium

*Alberto Montero, MD, MBA
University Hospitals Seidman Cancer Center*

Educational Objectives

At the conclusion of this activity, the participant should be better able to:

- 1 Identify basic epidemiology and clinical outcomes in triple negative breast cancer (TNBC)
- 2 Indicate current clinical data supporting the use of PD-1 mAb therapy in combination with chemotherapy in TNBC
- 3 Cite novel therapeutic targets based on ongoing research performed at CCCC which could be potentially exploited to overcome immunotherapy resistance in TNBC

Accreditation and Credit Designation Statements

Case Western Reserve University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Case Western Reserve University School of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures:

All relevant financial relationships have been mitigated. This activity's planners and speaker(s) have made the following disclosures:

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Stan Gerson, MD	Course Director	Nothing to disclose - 06/07/2022
Alberto Montero, MD, MBA	Faculty	Nothing to disclose - 10/06/2022
J A Diehl, PhD	Other Planning Committee Member	Nothing to disclose - 01/17/2023
Ruth Keri, PhD	Other Planning Committee Member	Nothing to disclose - 06/07/2022